All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
During ICML 2019 in Lugano, Switzerland, the Lymphoma Hub were pleased to speak to Michael Dickinson from Peter MacCallum Cancer Center, Melbourne, AU, about the efficacy of the novel T-cell bispecific engaging antibody, CD20-TCB (RG6026), for the treatment of relapsed/refractory non-Hodgkin lymphoma (NHL).
Michael Dickinson describes CD20-TCB as a CD20 CD3 bispecific antibody, which was tested in non-Hodgkin lymphoma, targeting CD20. Despite toxicities being observed in patients, it is still early days, with promising results for patients with a very aggressive refractory condition.
ICML 2019 | Efficacy of novel T-cell bispecific engaging antibody, CD20-TCB (RG6026), for R/R NHL
Phase I study of CD20-TCB, a novel T-cell-engaging bispecific antibody, in R/R NHL
During the 25th Congress of the European Hematology Association (EHA), the Lymphoma Hub spoke to Michael Dickinson, Peter MacCallum Cancer Centre and The Royal...
Chemotherapy-free approaches for indolent NHL and MCL
This month we will take a closer look at chemotherapy-free treatment strategies for iNHL and MCL. First, let's recap on some of the relevant material that we covered earlier this year.
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox